New Vaccine Deals Are Making One High-Growth Stock Much Less Risky

One of the most compelling stories of scientific advancement coming out of the pandemic has been BioNTech (NASDAQ: BNTX). The German biopharmaceutical company created the first vaccine using messenger RNA (mRNA) to receive authorization. With its partner Pfizer, it has delivered hundreds of millions of doses and inked agreements to supply billions more. That's been great for shareholders.

Looking forward, investors are baking in the windfall and already asking what comes next. Unlike many biotechs, the company is now in a strong enough financial position to pursue several potential breakthrough therapies, making it more likely that one of them will be successful. It also makes BioNTech a rapidly growing biotech that gets less risky with each new drug program it pursues.

Image source: Getty Images.

Source Fool.com